Concurrently, EMPA treatment effectively suppressed activation of the NF-κB/NLRP3 signaling pathway, accompanied by reduced levels of IL-1β and IL-18, suggesting decreased levels of cardiomyocyte pyroptosis and markedly alleviated inflammatory infiltration and myocardial fibrosis. The gene discussed is NFKB1; the disease is Myocardial fibrosis.